NASDAQ
TRIB

Trinity Biotech plc

Diagnostics & Research
Healthcare

Prices are adjusted according to historical splits.

Trinity Biotech plc Stock Price

Vitals

Today's Low:
$0.75
Today's High:
$0.9176
Open Price:
$0.9176
52W Low:
$0.63
52W High:
$1.41
Prev. Close:
$0.85
Volume:
20966

Company Statistics

Market Cap.:
$32.40 million
Book Value:
-0.173
Revenue TTM:
$73.93 million
Operating Margin TTM:
-18.43%
Gross Profit TTM:
$38.08 million
Profit Margin:
-46.72%
Return on Assets TTM:
-8.63%
Return on Equity TTM:
-864.36%

Company Profile

Trinity Biotech plc had its IPO on 1995-08-18 under the ticker symbol TRIB.

The company operates in the Healthcare sector and Diagnostics & Research industry. Trinity Biotech plc has a staff strength of 398 employees.

Stock update

Shares of Trinity Biotech plc opened at $0.92 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.75 - $0.92, and closed at $0.8.

This is a -5.88% slip from the previous day's closing price.

A total volume of 20,966 shares were traded at the close of the day’s session.

In the last one week, shares of Trinity Biotech plc have increased by +11.11%.

Trinity Biotech plc's Key Ratios

Trinity Biotech plc has a market cap of $32.40 million, indicating a price to book ratio of 2.8498 and a price to sales ratio of 0.5419.

In the last 12-months Trinity Biotech plc’s revenue was $73.93 million with a gross profit of $38.08 million and an EBITDA of $-12282000. The EBITDA ratio measures Trinity Biotech plc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Trinity Biotech plc’s operating margin was -18.43% while its return on assets stood at -8.63% with a return of equity of -864.36%.

In Q1, Trinity Biotech plc’s quarterly earnings growth was a negative -77.3% while revenue growth was a negative 21%.

Trinity Biotech plc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
1.3

Its diluted EPS in the last 12-months stands at $-0.83 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 1.3. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Trinity Biotech plc’s profitability.

Trinity Biotech plc stock is trading at a EV to sales ratio of 1.1936 and a EV to EBITDA ratio of 49.1213. Its price to sales ratio in the trailing 12-months stood at 0.5419.

Trinity Biotech plc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$92.10 million
Total Liabilities
$17.34 million
Operating Cash Flow
$0
Capital Expenditure
$1.14 million
Dividend Payout Ratio
0%

Trinity Biotech plc ended 2023 with $92.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $92.10 million while shareholder equity stood at $-2176000.00.

Trinity Biotech plc ended 2023 with $0 in deferred long-term liabilities, $17.34 million in other current liabilities, 1963000.00 in common stock, $-26695000.00 in retained earnings and $12.54 million in goodwill. Its cash balance stood at $6.58 million and cash and short-term investments were $6.58 million. The company’s total short-term debt was $210,000 while long-term debt stood at $63.14 million.

Trinity Biotech plc’s total current assets stands at $46.67 million while long-term investments were $1.50 million and short-term investments were $17.12 million. Its net receivables were $17.59 million compared to accounts payable of $17.05 million and inventory worth $22.50 million.

In 2023, Trinity Biotech plc's operating cash flow was $0 while its capital expenditure stood at $1.14 million.

Comparatively, Trinity Biotech plc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
$0.8
52-Week High
$1.41
52-Week Low
$0.63
Analyst Target Price
$7

Trinity Biotech plc stock is currently trading at $0.8 per share. It touched a 52-week high of $1.41 and a 52-week low of $1.41. Analysts tracking the stock have a 12-month average target price of $7.

Its 50-day moving average was $0.85 and 200-day moving average was $0.99 The short ratio stood at 0.24 indicating a short percent outstanding of 0%.

Around 2928.7% of the company’s stock are held by insiders while 2351.9% are held by institutions.

Frequently Asked Questions About Trinity Biotech plc

The stock symbol (also called stock or share ticker) of Trinity Biotech plc is TRIB

The IPO of Trinity Biotech plc took place on 1995-08-18

Similar Industry Stocks (Diagnostics & Research)

Last Price
Chg
Chg%
$32.29
0.25
+0.78%
$17.55
0.37
+2.15%
$11.14
0.06
+0.54%
$386.15
-25.05
-6.09%
$168.1
-8
-4.54%
$38.44
0.22
+0.58%
$123.3
-9.45
-7.12%
$8.55
0.2
+2.4%
$1189.15
-16.9
-1.4%
$98.28
-3.52
-3.46%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Address

IDA Business Park, Bray, Ireland